Anderson D, Yardley-Jones A, Vives-Bauza C, Chua-Anusorn W, Cole C, Webb J
TNO BIBRA International Ltd, Carshalton, Surrey, UK.
Teratog Carcinog Mutagen. 2000;20(5):251-64. doi: 10.1002/1520-6866(2000)20:5<251::aid-tcm1>3.0.co;2-f.
Impairment of haemoglobin synthesis occurs in the genetic diseases known as thalassaemia. The consequent chronic anaemia leads to increased dietary iron absorption which results in iron overload. Treatment through regular blood transfusions increases oxygen capacity, but also adds iron from haemoglobin. An essential treatment, in parallel with transfusions, is the use of chelating agents to remove the excess iron. Thalassaemia patients are particularly at risk of free radical damage. Human lymphocytes from normal individuals can be investigated in vitro as a model system in the presence of free radicals in the Comet assay. This assay measures DNA damage, particularly DNA strand breakage. We examined cells from an Australian thalassaemic patient (sickle/beta thal double heterozygote-sickle phenotype) who had not yet received chelation therapy to determine if the cells were more sensitive to simulated iron overload and to haemosiderins. Lymphocytes from the patient were received as frozen samples after 28 h on dry ice and then placed in liquid nitrogen. Normal lymphocytes frozen under the same conditions and normal nonfrozen lymphocytes were compared. The lymphocytes from a normal female did not respond in vitro to ferric chloride (FeCl(3)) or haemosiderin but did to ferrous chloride (FeCl(2)) and ferrous sulphate (FeSO(4)). Deferoxamine appeared to reduce the response to FeCl(2) and FeSO(4) but deferiprone did not. When the lymphocytes from the nonchelated patient were treated with FeSO(4) and hydrogen peroxide, deferoxamine and deferiprone both reduced the response. Over the same dose range of iron salt (FeSO(4)), the lymphocytes from the thalassaemic patient were more sensitive, with much higher background levels of damage and induced damage. When deferiprone and deferoxamine were compared over a nontoxic range, deferiprone appeared to produce a greater reduction of damage in lymphocytes of the thalassaemia patient. Ferritin iron appears to be more available than haemosiderin iron in reactions leading to DNA damage. Haemosiderin containing higher amounts of the goethite-like (alpha-FeOOH) iron oxide phase leads to lower levels of DNA damage.
血红蛋白合成障碍发生在被称为地中海贫血的遗传性疾病中。随之而来的慢性贫血导致饮食中铁吸收增加,从而导致铁过载。通过定期输血进行治疗可提高氧容量,但也会从血红蛋白中添加铁。与输血同时进行的一项重要治疗是使用螯合剂去除多余的铁。地中海贫血患者尤其有自由基损伤的风险。在彗星试验中,可在存在自由基的情况下,将来自正常个体的人淋巴细胞作为体外模型系统进行研究。该试验测量DNA损伤,特别是DNA链断裂。我们检查了一名尚未接受螯合治疗的澳大利亚地中海贫血患者(镰状/β地中海贫血双重杂合子 - 镰状表型)的细胞,以确定这些细胞是否对模拟的铁过载和含铁血黄素更敏感。患者的淋巴细胞在干冰上放置28小时后作为冷冻样本接收,然后置于液氮中。将在相同条件下冷冻的正常淋巴细胞和正常未冷冻的淋巴细胞进行比较。来自正常女性的淋巴细胞在体外对氯化铁(FeCl₃)或含铁血黄素无反应,但对氯化亚铁(FeCl₂)和硫酸亚铁(FeSO₄)有反应。去铁胺似乎降低了对FeCl₂和FeSO₄的反应,但地拉罗司没有。当未接受螯合治疗的患者的淋巴细胞用FeSO₄和过氧化氢处理时,去铁胺和地拉罗司都降低了反应。在相同剂量范围内的铁盐(FeSO₄)下,地中海贫血患者的淋巴细胞更敏感,具有更高的背景损伤水平和诱导损伤水平。当地拉罗司和去铁胺在无毒范围内进行比较时,地拉罗司似乎对地中海贫血患者淋巴细胞的损伤减少作用更大。在导致DNA损伤的反应中,铁蛋白铁似乎比含铁血黄素铁更易利用。含有较高含量针铁矿样(α - FeOOH)氧化铁相的含铁血黄素导致较低水平的DNA损伤。